PMID- 24462980
OWN - NLM
STAT- MEDLINE
DCOM- 20141125
LR  - 20211021
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Print)
IS  - 1083-8791 (Linking)
VI  - 20
IP  - 5
DP  - 2014 May
TI  - Sustained donor engraftment in recipients of double-unit cord blood 
      transplantation is possible despite donor-specific human leukoctye antigen 
      antibodies.
PG  - 735-9
LID - S1083-8791(14)00048-2 [pii]
LID - 10.1016/j.bbmt.2014.01.017 [doi]
AB  - The impact of human leukocyte antigen (HLA) donor-specific antibodies (DSA) on 
      cord blood (CB) engraftment is controversial. We evaluated the influence of 
      pre-existing HLA-antibodies (HLA-Abs) on engraftment in 82 double-unit CB 
      recipients (median age, 48 years) who underwent transplantation for hematologic 
      malignancies. Of 28 patients (34%) with HLA-Abs, 12 had DSA (median mean 
      fluorescence intensity 5255; range, 1057 to 9453). DSA patients had acute 
      leukemia (n = 11) or myelodysplasia (n = 1) and all received either high-dose or 
      reduced-intensity (but myeloablative) conditioning. After myeloablative CB 
      transplantation (CBT) (n = 67), sustained donor engraftment was observed in 95% 
      without HLA-Abs (median, 23 days), 100% with nonspecific HLA-Abs (median, 23 
      days), and 92% with DSA (median, 31 days, P = .48). Of 6 patients with HLA-Abs to 
      1 unit, 3 engrafted with that unit and 3 with the other. Of 6 patients with 
      HLA-Abs against both units, 1 had graft failure despite being 100% donor, and 5 
      engrafted with 1 unit. Successful donor engraftment is possible in patients with 
      DSA after myeloablative double-unit CBT. Our data suggest potential deleterious 
      effects of DSA can be abrogated in patients with hematologic malignancies.
CI  - Copyright (c) 2014 American Society for Blood and Marrow Transplantation. Published 
      by Elsevier Inc. All rights reserved.
FAU - Dahi, Parastoo B
AU  - Dahi PB
AD  - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial 
      Sloan-Kettering Cancer Center, New York, New York; Department of Medicine, Weill 
      Cornell Medical College, New York, New York.
FAU - Barone, Jonathan
AU  - Barone J
AD  - Department of Histocompatibility/Molecular Genetics, American Red Cross Blood 
      Services/Penn Jersey Region, Philadelphia, Pennsylvania.
FAU - Devlin, Sean M
AU  - Devlin SM
AD  - Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, 
      New York.
FAU - Byam, Courtney
AU  - Byam C
AD  - Pediatric Bone Marrow Transplantation Service, Department of Pediatrics, Memorial 
      Sloan-Kettering Cancer Center, New York, New York.
FAU - Lubin, Marissa
AU  - Lubin M
AD  - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial 
      Sloan-Kettering Cancer Center, New York, New York.
FAU - Ponce, Doris M
AU  - Ponce DM
AD  - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial 
      Sloan-Kettering Cancer Center, New York, New York; Department of Medicine, Weill 
      Cornell Medical College, New York, New York.
FAU - Giralt, Sergio
AU  - Giralt S
AD  - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial 
      Sloan-Kettering Cancer Center, New York, New York; Department of Medicine, Weill 
      Cornell Medical College, New York, New York.
FAU - Kernan, Nancy A
AU  - Kernan NA
AD  - Pediatric Bone Marrow Transplantation Service, Department of Pediatrics, Memorial 
      Sloan-Kettering Cancer Center, New York, New York.
FAU - Scaradavou, Andromachi
AU  - Scaradavou A
AD  - Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, 
      New York.
FAU - Hsu, Susan H
AU  - Hsu SH
AD  - Department of Histocompatibility/Molecular Genetics, American Red Cross Blood 
      Services/Penn Jersey Region, Philadelphia, Pennsylvania.
FAU - Barker, Juliet N
AU  - Barker JN
AD  - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial 
      Sloan-Kettering Cancer Center, New York, New York; Department of Medicine, Weill 
      Cornell Medical College, New York, New York. Electronic address: 
      barkerj@mskcc.org.
LA  - eng
GR  - P01 CA023766/CA/NCI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P01 CA23766/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140123
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
RN  - 0 (Myeloablative Agonists)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antibodies/*blood
MH  - Child
MH  - Child, Preschool
MH  - Cord Blood Stem Cell Transplantation/*methods
MH  - Female
MH  - *Graft Survival
MH  - Graft vs Host Disease/pathology/*prevention & control
MH  - HLA Antigens/blood
MH  - Hematologic Neoplasms/blood/mortality/pathology/*therapy
MH  - Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myeloablative Agonists/*therapeutic use
MH  - Survival Analysis
MH  - *Transplantation Conditioning
MH  - Transplantation, Homologous
PMC - PMC3984623
MID - NIHMS560460
OTO - NOTNLM
OT  - Cord blood transplantation
OT  - Engraftment
OT  - Human leukocyte antigen (HLA) antibodies
COIS- Disclosure of Conflicts of Interest The authors have no relevant conflicts of 
      interest to declare.
EDAT- 2014/01/28 06:00
MHDA- 2014/12/15 06:00
PMCR- 2015/05/01
CRDT- 2014/01/28 06:00
PHST- 2013/08/20 00:00 [received]
PHST- 2014/01/18 00:00 [accepted]
PHST- 2014/01/28 06:00 [entrez]
PHST- 2014/01/28 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
AID - S1083-8791(14)00048-2 [pii]
AID - 10.1016/j.bbmt.2014.01.017 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2014 May;20(5):735-9. doi: 
      10.1016/j.bbmt.2014.01.017. Epub 2014 Jan 23.